Our Speakers
Discover the pioneering minds headlining the Borealis Psychedelic Science Summit 2025. Below, you’ll find our growing roster of experts. Click on each speaker to learn more about their background, their summit topic, and the insights they’ll share in Stockholm. We’ll be updating this page as more speakers are confirmed, so check back often.
Keynote
Dr. Julie Holland, NYT-bestselling psychiatrist and MAPS advisor, pioneers MDMA and cannabis-assisted therapies.
Dr. Matthew W. Johnson (Johns Hopkins) is a leading psychedelic researcher, known for work on psilocybin, addiction, and behavioral pharmacology
Speakers
Dr. Paul Liknaitzky, leading psychedelic researcher at Monash, spearheads transformative clinical trials and novel therapies in Australia.
Dr. Gerhard Gründer, psychiatrist at CIMH Mannheim, pioneers advanced imaging and psychedelic research in severe mental disorders.
Dr. Christoffer Timmermann, researcher at University College London, leads the DMT Research Group exploring psychedelics’ effects on brain and mind.
Oxford psychiatrist researching mood disorders and psychedelics; led Compass Pathways' phase IIb trial and is among the top 1% most cited researchers.
Psychologist and researcher in Zurich and Basel studying psychedelics; also practices PAT and trains therapists through the Swiss Medical Association.
Dr. Dea Stenbæk researches psilocybin’s effects on the brain, focusing on serotonin, neurocognition, and therapeutic setting using PET imaging.
Philosopher Dr. Peter Sjöstedt-Hughes (Exeter) explores mind & psychedelics, TEDx & BBC speaker, co-directs Breaking Convention, author of numerous key papers
Joost Breeksema, researcher & OPEN Foundation director, bridges science, ethics & policy in psychedelics, leading EU projects & ICPR conference.
Pehr Granqvist, Professor of Psychology at Stockholm University, researches attachment, religion, and psychedelics’ role in fostering security.
_short.jpg?2025-08-27T14:48:20.307Z)
Filipa Sampaio, Associate Professor at Uppsala University, studies mental & child health economics, leading evaluations of interventions and real-world decision research.
Cristina Kroon, Dr.rer.nat, neuroscientist & TAIP advisor, advances psychedelic therapies in Estonia and bridges brain research, policy & innovation.
Dr. Viljar Veede, psychiatrist in Estonia, pioneered ketamine therapy, co-founded SA TAIP, and advances psychedelic-assisted psychotherapy.
Tali Avron, Clinical Research Manager, ex-MAPS Europe, leads psychedelic trials & women-focused studies, and co-founded Psychedelic Women Network.
Oliver Rumle Hovmand, MD, PhD, researches psychotherapy & leads a psilocybin trial for anorexia, authoring work on methods & therapeutic use.
Naina Eira Gupta, Harvard & Exeter researcher, bridges Buddhism & psychedelic science, focusing on unitive states & meditation-based protocols.
Dr. Margareta Wärja, psychotherapist & music therapist, co-founded Expressive Arts Stockholm and researches Guided Imagery & Music in therapy.
Joel Gruneau Brulin, clinical psychologist & Stockholm University researcher, studies attachment, trust & psychedelics’ role in emotional processing & healing.
Esenia Cassidy, PhD student at OSU, researches psychedelics, attachment, gender & trauma, co-founding labs bridging social justice & science.
David Sjöström, child & adolescent psychiatry resident, researches youth psychedelic use & coordinates a psilocybin trial for anorexia at Lund.
Angelika is a psychotherapist & psychedelic research therapist working in trials, retreats & education, with focus on women’s mental health.
Psychiatrist & PhD student researching psychedelic-informed ketamine & psilocybin trials, with roots in yoga, meditation & harm reduction.
Guy Simon, psychotherapist & PhD candidate, explores trauma, healing & psychedelic experiences, uniting clinical practice with anthropology.
Cecilie B. Endresen (NAPSi) is a psychologist and advocate for ethical, inclusive psychedelic science, bridging clinical work, ecology, and leadership
Psychologist and researcher focused on psychedelic integration, harm reduction, and clinical support, currently leading a national study in Poland.
Josh Hardman, founder of Psychedelic Alpha, offers data-driven insights on psychedelics, spanning business, policy, and research.
Dr. Maria Beckman, psychologist at Karolinska, researches psilocybin therapies and therapist–patient dynamics in clinical trials.
Dr. Leor Roseman, researcher at University of Exeter, merges neuroscience, anthropology, and conflict resolution in psychedelic studies.
Licensed psychologist specialized in neuropsychology, active in psilocybin research, therapy training, and psychedelic integration.
MD and PhD student studying psilocybin for cancer-related depression, focusing on clinical effects, expectancy, and brain changes in CAPSI trial.
Dr. Hendricks studies psilocybin for addiction, pain, and demoralization, focusing on vulnerable groups and leads multiple clinical trials at UAB.
Prof. Schoevers studies mood disorders and psychedelic treatments, leads the PsyPal trial on psilocybin in palliative care and pioneers esketamine use
Prof. Camilla Lindvall Dahlgren (ONH) researches eating disorders and leads work on ketamine-assisted therapy and clinical innovation in Norway.
Dr. Lowan Stewart is a leading expert in ketamine and psychedelic therapies, co-founding clinics and research groups across Norway and the U.S.
Dr. Rebecca Böhme (Linköping Univ.) studies the sense of self through neuroscience, brain imaging, and psychedelic interventions.
Dr. Kangaslampi (Tampere Univ.) researches trauma, memory, and psychedelics, and holds leadership roles in key Finnish psychological associations.
Dr. Jason Luoma researches shame and connection, combining ACT and psychedelic therapy to foster compassion and belonging.
Dr. Jussi Jylkkä (Åbo Akademi) researches psychedelic insights, belief change, their place within cognitive psychology and the scientific worldview.
Prof. Gitte Moos Knudsen (Rigshospitalet/Copenhagen) studies brain disorders and treatment response using PET, fMRI, and precision neuroimaging.
Ulf Bremberg (Osmond Labs) coordinates EU-funded psilocybin research and works to advance psychedelic therapy integration in healthcare.
Prof. Suresh Muthukumaraswamy (Univ. of Auckland) studies how psychedelics and therapies alter brain function, leading large trials on LSD & ketamine.
Dr. Ingrid Autran (Østfold Hospital) researches ketamine and MDMA therapy, and founded harm-reduction group Safe Space and Aurora Clinics.
Ian Roullier co-founded PsyPAN to center participant voices in psychedelic care, drawing on his lived experience in psilocybin trials and advocacy.
Dr. Eva Henje researches youth depression, trauma therapies, and MDMA-assisted treatment, with clinical roles in Sweden, Oslo, and the Netherlands.
Dr. Balazs Szigeti pioneers citizen science in psychedelics, leading the largest microdosing study with his novel self-blinding methodology.
Moderators
Clinical psychologist & PhD student at Karlstad Univ. Focuses on psychedelic harm reduction, co-founded NVP & serves on Swedish Association for Psychedelic Therapy board.
Cecilie B. Endresen (NAPSi) is a psychologist and advocate for ethical, inclusive psychedelic science, bridging clinical work, ecology, and leadership
Joost Breeksema, researcher & OPEN Foundation director, bridges science, ethics & policy in psychedelics, leading EU projects & ICPR conference.
Psychiatrist & postdoc at Gothenburg Univ. Researches antidepressant effects, prescribing patterns & trials incl. novel dopaminergic drugs.
Albert is an investor and philanthropist, funding mechanistic, clinical, and phenomenological psychedelic research.
Licensed psychologist specialized in neuropsychology, active in psilocybin research, therapy training, and psychedelic integration.